Clinical Trials Directory

Trials / Unknown

UnknownNCT01249053

Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
China Medical University Hospital · Academic / Other
Sex
All
Age
25 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Optic atrophy type 1(OPA1) is a nuclear dynamin-related GTPase, targeted to the inner mitochondrial membrane, which plays a role in mitochondrial fusion. Mitochondria fusion is associated with process of apoptosis. . OPA1 plays an important role in the mitochondrial bioenergetics and mitochondrial networks. The changes in mitochondrial shape and mitochondrial bioenergetics may be cause of the disease. In this study, we investigate the expression of OPA1 in lung adenocarcinoma (LADC) cells and tissue.

Conditions

Timeline

Start date
2010-08-01
First posted
2010-11-29
Last updated
2010-11-29

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT01249053. Inclusion in this directory is not an endorsement.